Literature DB >> 32374728

Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness.

Yuki Seki1, Yukio Oda2, Norio Sugaya3.   

Abstract

During influenza epidemics, Japanese clinicians routinely perform rapid influenza diagnostic tests (RIDTs) in the examination of patients who have an influenza-like illness, and patients with positive test results, including otherwise healthy individuals, are treated with anti-influenza drugs. However, it was recently reported that the sensitivity of RIDTs was extremely low in adult patients. We examined the sensitivity and specificity of an RIDT that is widely used in Japan, ImunoAce Flu (TAUNS, Shizuoka, Japan), in comparison to reverse transcriptase polymerase chain reaction (RT-PCR). The sensitivity and specificity of the ImunoAce Flu test were 97.1% (95%CI: 93.8-98.9) and 89.2% (95%CI: 84.1-93.1), respectively. The ImunoAce Flu test is designed to not only detect influenza A or B, but also to detect H1N1pdm09 with the use of an additional test kit (Linjudge FluA/pdm). Its sensitivity and specificity for A/H1N1pdm09 were 97.6% (95%CI: 87.4-99.9) and 92.6% (95%CI: 82.1-97.9), respectively. Thus, by consecutively testing patients with the ImunoAce Flu test followed by the Linjudge FluA/pdm test, we are able to diagnose whether a patient has A/H1N1pdm09 or A/H3N2 infection within a short time. The reliability of rapid test results seems to be much higher in Japan than in other countries, because approximately 90% of influenza patients are tested and treated within 48 hours after the onset of illness, when the influenza viral load in the upper respiratory tract is high. From the Japanese experience, RIDTs are sufficiently sensitive and highly useful, if patients are tested within 48 hours after the onset of illness.

Entities:  

Year:  2020        PMID: 32374728     DOI: 10.1371/journal.pone.0231217

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  4 in total

1.  Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season.

Authors:  Masayoshi Shinjoh; Norio Sugaya; Yoshio Yamaguchi; Ichiro Ookawara; Yuji Nakata; Atsushi Narabayashi; Munehiro Furuichi; Naoko Yoshida; Akinobu Kamei; Yuu Kuramochi; Akimichi Shibata; Motoko Shimoyamada; Hisataka Nakazaki; Naohiko Maejima; Erika Yuasa; Eriko Araki; Naonori Maeda; Takuma Ohnishi; Mitsuhiro Nishida; Nobuhiko Taguchi; Makoto Yoshida; Kenichiro Tsunematsu; Meiwa Shibata; Yasuhiro Hirano; Shinichiro Sekiguchi; Chiharu Kawakami; Keiko Mitamura; Takao Takahashi
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

2.  Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.

Authors:  Masayoshi Shinjoh; Munehiro Furuichi; Hisato Kobayashi; Yoshio Yamaguchi; Naonori Maeda; Mizuki Yaginuma; Ken Kobayashi; Taisuke Nogayama; Michiko Chiga; Mio Oshima; Yuu Kuramochi; Go Yamada; Atsushi Narabayashi; Ichiro Ookawara; Mitsuhiro Nishida; Kenichiro Tsunematsu; Isamu Kamimaki; Motoko Shimoyamada; Makoto Yoshida; Akimichi Shibata; Yuji Nakata; Nobuhiko Taguchi; Keiko Mitamura; Takao Takahashi
Journal:  Vaccine       Date:  2022-04-11       Impact factor: 4.169

3.  Association between visceral fat and influenza infection in Japanese adults: A population-based cross-sectional study.

Authors:  Keita Kinoshita; Naoki Ozato; Tohru Yamaguchi; Kenta Mori; Yoshihisa Katsuragi; Takuji Yasukawa; Koichi Murashita; Shigeyuki Nakaji; Kazushige Ihara
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

4.  Immunodominant regions prediction of nucleocapsid protein for SARS-CoV-2 early diagnosis: a bioinformatics and immunoinformatics study.

Authors:  Yufeng Dai; Hongzhi Chen; Siqi Zhuang; Xiaojing Feng; Yiyuan Fang; Haoneng Tang; Ruchun Dai; Lingli Tang; Jun Liu; Tianmin Ma; Guangming Zhong
Journal:  Pathog Glob Health       Date:  2020-11-16       Impact factor: 2.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.